A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows ...
Apr 30, 2019
0
1
Current standard imaging techniques for initial staging of prostate cancer often underestimate the extent of disease beyond the prostate. A study featured in The Journal of Nuclear Medicine's November issue demonstrates that ...
Nov 8, 2018
0
5
A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the ...
Sep 18, 2023
0
23
A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in the field of nuclear medicine and molecular imaging. In the article, Irène Buvat, Ph.D., and ...
Mar 27, 2023
0
20
A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. In the study, the imaging agent—Ga-68 ...
Sep 17, 2015
0
142
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and peer medical groups have issued appropriate use criteria (AUC) for prostate-specific membrane antigen (PSMA) PET imaging. The criteria, published in the January ...
Jan 7, 2022
0
4
In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That's where 3D-printed organ models of varying ...
Dec 5, 2016
0
51
A study published in the January issue of The Journal of Nuclear Medicine reports that approximately one out of every two Medicare patients with non-small cell lung cancer (NSCLC) does not receive the appropriate imaging ...
Jan 18, 2023
0
1
Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of ...
Feb 5, 2018
0
97
A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with ...
Jan 5, 2017
0
0
